Literature DB >> 22000604

The shifting interface between IBS and IBD.

Robin Spiller1, Ching Lam.   

Abstract

Recent data developing from the study of postinfectious IBS has challenged the belief that IBS is a purely psychological disorder. Distinct abnormalities of the gut mucosa have been reported including immune activation and increased release of inflammatory mediators with some overlap with IBD. New studies show that genetic factors which predispose to IBD are also associated with IBS. A common feature is impaired gut barrier function which appears to precede the development of IBD while in IBS it may be the result of either a preceding infection or psychosocial stress. Stress can activate mast cells which are a feature in most but not all IBS series. Anti-inflammatory treatments targeting activated mast cells may benefit IBS patients but currently the evidence is weak and larger trials are needed. Changes in the commensal microbiota have been recently described with a "dysbiosis" in CD characterised by reduced diversity. Inconsistent changes have also been described in IBS but studies controlling for antibiotic use and differences in diet and bowel habit are needed before definitive conclusions can be made.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22000604     DOI: 10.1016/j.coph.2011.09.009

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  8 in total

1.  High-Fat Diet and Antibiotics Cooperatively Impair Mitochondrial Bioenergetics to Trigger Dysbiosis that Exacerbates Pre-inflammatory Bowel Disease.

Authors:  Jee-Yon Lee; Stephanie A Cevallos; Mariana X Byndloss; Connor R Tiffany; Erin E Olsan; Brian P Butler; Briana M Young; Andrew W L Rogers; Henry Nguyen; Kyongchol Kim; Sang-Woon Choi; Eunsoo Bae; Je Hee Lee; Ui-Gi Min; Duk-Chul Lee; Andreas J Bäumler
Journal:  Cell Host Microbe       Date:  2020-07-14       Impact factor: 21.023

2.  Restraint stress induces and exacerbates intestinal inflammation in interleukin-10 deficient mice.

Authors:  Seong-Joon Koh; Ji Won Kim; Byeong Gwan Kim; Kook Lae Lee; Joo Sung Kim
Journal:  World J Gastroenterol       Date:  2015-07-28       Impact factor: 5.742

3.  Protective effect of naringenin against experimental colitis via suppression of Toll-like receptor 4/NF-κB signalling.

Authors:  Wei Dou; Jingjing Zhang; Aning Sun; Eryun Zhang; Lili Ding; Subhajit Mukherjee; Xiaohui Wei; Guixin Chou; Zheng-Tao Wang; Sridhar Mani
Journal:  Br J Nutr       Date:  2013-03-18       Impact factor: 3.718

4.  Fructose transporters GLUT5 and GLUT2 expression in adult patients with fructose intolerance.

Authors:  Clive H Wilder-Smith; Xinhua Li; Sherry Sy Ho; Sai Mun Leong; Reuben K Wong; Evelyn Sc Koay; Ronaldo P Ferraris
Journal:  United European Gastroenterol J       Date:  2014-02       Impact factor: 4.623

5.  Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model.

Authors:  Rebeca Martín; Sylvie Miquel; Florian Chain; Jane M Natividad; Jennifer Jury; Jun Lu; Harry Sokol; Vassilia Theodorou; Premysl Bercik; Elena F Verdu; Philippe Langella; Luis G Bermúdez-Humarán
Journal:  BMC Microbiol       Date:  2015-03-21       Impact factor: 3.605

Review 6.  Irritable bowel syndrome: new insights into symptom mechanisms and advances in treatment.

Authors:  Robin Spiller
Journal:  F1000Res       Date:  2016-04-29

Review 7.  Irritable bowel syndrome and inflammatory bowel disease overlap syndrome: pieces of the puzzle are falling into place.

Authors:  Rafiz Abdul Rani; Raja Affendi Raja Ali; Yeong Yeh Lee
Journal:  Intest Res       Date:  2016-10-17

8.  Fructose and lactose intolerance and malabsorption testing: the relationship with symptoms in functional gastrointestinal disorders.

Authors:  C H Wilder-Smith; A Materna; C Wermelinger; J Schuler
Journal:  Aliment Pharmacol Ther       Date:  2013-04-09       Impact factor: 8.171

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.